This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novavax (NVAX) Seeks Accelerated Approval Pathway for NanoFlu
by Zacks Equity Research
Novavax (NVAX) seeks to use accelerated approval pathway for its influenza vaccine candidate, NanoFlu, in the United States.
Will Novavax Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Novavax.
Novavax Enters Oversold Territory
by Zacks Equity Research
Novavax, Inc. (NVAX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Novavax' Shares Drop as FDA Advises Another Study for Resvax
by Zacks Equity Research
FDA recommends Novavax (NVAX) to conduct additional phase III study for its respiratory syncytial virus (RSV) vaccine candidate for infants, ResVax.
Novavax (NVAX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Novavax (NVAX) delivered earnings and revenue surprises of 8.33% and -17.04%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Is the Options Market Predicting a Spike in Novavax (NVAX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.
What's in the Cards for Novavax (NVAX) This Earnings Season?
by Zacks Equity Research
Novavax (NVAX) is likely to provide update on the path forward for its two lead vaccine candidates.
Zacks Value Trader Highlights: Novavax, J.C. Penney, Pier 1 Imports, Tilray and Aurora Cannabis
by Zacks Equity Research
Zacks Value Trader Highlights: Novavax, J.C. Penney, Pier 1 Imports, Tilray and Aurora Cannabis
Should You Buy Lottery Stocks?
by Tracey Ryniec
Like playing the lottery, some stocks lure in investors with the promise of possible riches.
Novavax (NVAX) Stock Moves -0.67%: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $0.57, marking a -0.67% move from the previous day.
Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $0.59, marking a +1.57% move from the previous day.
Novavax (NVAX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $0.53, marking a +0.21% move from the previous day.
Do Options Traders Know Something About Novavax (NVAX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.
Is a Beat in Store for Catabasis (CATB) This Earnings Season?
by Zacks Equity Research
Catabasis (CATB) progresses with DMD candidate, edasalonexent. However, operating expenses are likely to be lower.
What's in the Cards for Novavax (NVAX) This Earnings Season?
by Zacks Equity Research
Novavax (NVAX) is expected to provide updates on its lead vaccine candidate, Resvax when it reports fourth-quarter 2018 results.
Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed the most recent trading day at $2.19, moving -0.45% from the previous trading session.
Novavax (NVAX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $2.30, marking a +0.44% move from the previous day.
Is Novavax (NVAX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (NVAX) Outperforming Other Medical Stocks This Year?
Novavax (NVAX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Novavax (NVAX) delivered earnings and revenue surprises of 0.00% and -23.91%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Novavax (NVAX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed at $1.92 in the latest trading session, marking a +1.05% move from the prior day.
What's in the Cards for Novavax (NVAX) This Earnings Season?
by Zacks Equity Research
Investors are looking forward to Novavax's (NVAX) updates on its pipeline candidates when it reports third-quarter 2018 results.
Will Novavax (NVAX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Do Options Traders Know Something About Novavax (NVAX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.
Novavax (NVAX) Catches Eye: Stock Jumps 7.6%
by Zacks Equity Research
Novavax (NVAX) shares rose nearly 8% in the last trading session, amid huge volumes.
Is the Options Market Predicting a Spike in Novavax (NVAX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.